JP2001515920A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515920A5
JP2001515920A5 JP2000510776A JP2000510776A JP2001515920A5 JP 2001515920 A5 JP2001515920 A5 JP 2001515920A5 JP 2000510776 A JP2000510776 A JP 2000510776A JP 2000510776 A JP2000510776 A JP 2000510776A JP 2001515920 A5 JP2001515920 A5 JP 2001515920A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
sequence
seq
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000510776A
Other languages
English (en)
Japanese (ja)
Other versions
JP4318398B2 (ja
JP2001515920A (ja
Filing date
Publication date
Priority claimed from DE19739685A external-priority patent/DE19739685A1/de
Application filed filed Critical
Publication of JP2001515920A publication Critical patent/JP2001515920A/ja
Publication of JP2001515920A5 publication Critical patent/JP2001515920A5/ja
Application granted granted Critical
Publication of JP4318398B2 publication Critical patent/JP4318398B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000510776A 1997-09-10 1998-09-10 クロストリジウム・ディフィシレ・トキシンa Expired - Fee Related JP4318398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19739685.2 1997-09-10
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
PCT/EP1998/005759 WO1999012971A2 (de) 1997-09-10 1998-09-10 Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine

Publications (3)

Publication Number Publication Date
JP2001515920A JP2001515920A (ja) 2001-09-25
JP2001515920A5 true JP2001515920A5 (enExample) 2006-01-05
JP4318398B2 JP4318398B2 (ja) 2009-08-19

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510776A Expired - Fee Related JP4318398B2 (ja) 1997-09-10 1998-09-10 クロストリジウム・ディフィシレ・トキシンa

Country Status (11)

Country Link
US (2) US6667035B1 (enExample)
EP (1) EP0994904B1 (enExample)
JP (1) JP4318398B2 (enExample)
CN (1) CN1273588A (enExample)
AT (1) ATE254139T1 (enExample)
AU (1) AU9742698A (enExample)
BR (1) BR9815367A (enExample)
CA (1) CA2303202C (enExample)
DE (2) DE19739685A1 (enExample)
ES (1) ES2210832T3 (enExample)
WO (1) WO1999012971A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US20030054009A1 (en) * 2001-02-09 2003-03-20 Windle Henry J. Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル(Clostridiumdifficile)毒素に対する抗体およびその使用
ES2299776T3 (es) * 2004-06-16 2008-06-01 Straumann Holding Ag Membrana de barrera.
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20090280134A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) * 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
JP5591332B2 (ja) * 2009-07-27 2014-09-17 バイオディクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 試料中における変異したc.ディフィシル菌株を検出および同定するための方法
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012118693A1 (en) * 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
BR112014004162A2 (pt) * 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
NZ714516A (en) 2012-03-02 2017-06-30 Regeneron Pharma Human antibodies to clostridium difficile toxins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
EP0153519B1 (en) 1984-03-02 1988-06-01 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
BR9509903A (pt) 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Similar Documents

Publication Publication Date Title
JP2001515920A5 (enExample)
ATE494795T1 (de) Verbessertes bioaktives molkeproteinhydrolysat
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO1999057280A3 (en) Neisseria meningitidis antigens and compositions
DE60211535D1 (de) Verfahren zur herstellung von 2,5-diformylfuran aus kohlenhydraten
CA2429679A1 (en) Hd3a gene inducing flowering of plant and utilization thereof
DE69906075D1 (de) Salzbeständige modifizierte stärke
DE69936774D1 (de) Strukturproteine des virus, welches die pankreas-krankheit bei fischen verursacht, und ihre verwendungen
JPH10210974A5 (enExample)
ATE387857T1 (de) Calcium enthaltende süssigkeit
GB2364492B (en) Audio processing, e.g. for discouraging vocalisation or the production of complex sounds
NO20043665L (no) Fremgangsmate for fremstilling av 6.alfa.,9.alfa-difluor-17.alfa.-(1-okso-propoksy-11.beta.-hydroxy-16.alfa.-metyl-3-okso-androst-1,4-dien-17.beta.-tiokarboksylsyre
GB9929519D0 (en) Audio processing,e.g.for discouraging vocalisation or the production of complex sounds
ES2168404T3 (es) Elemento de construccion universal conteniendo elementos de resorte.
WO2003012106A3 (fr) Acide nucleique regulateur permettant l'expression d'un polynucleotide d'interet specifiquement dans l'endothelium d'une graine de plante, et ses applications.
WO2003057898A3 (en) Methods and materials for modulating p2x2
DE60033562D1 (de) Künstliche promotoren zür protein expression in pflanzen
GB9823457D0 (en) Audio processing, e.g. for discouraging vocalisation or the production of complex sounds
WO2002029053A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn correspondant
WO2002034901A8 (en) Protein kinase
WO2002046380A3 (en) Protein kinase